Intranasal oxycodone self-administration in non-dependent opioid abusers

Experimental and Clinical Psychopharmacology

Volumn 20, Issue 4, 2012, Pages 310-317

  Middleton, Lisa S ^a   Lofwall, Michelle R ^a   Nuzzo, Paul A ^a   Siegel, Anthony J ^a   Walsh, Sharon L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Intranasal; Opioid abuse; Oxycodone; Progressive ratio; Reinforcing efficacy; Self administration

Indexed keywords

OXYCODONE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; MALE; MONEY; OPIATE ADDICTION; OUTCOME ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INTRANASAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OPIOID-RELATED DISORDERS; OXYCODONE; PLACEBOS; SELF ADMINISTRATION;

EID: 84871911769     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0028327     Document Type: Article

References (40)

1. Altman, J. L., Meyer, R. E., Mirin, S. M., & McNamee, H. B. (1976). Opiate antagonists and the modification of heroin self-administration behavior in man: An experimental study. International Journal of the Addictions, 11, 485-499.
2. Ator, N. A., & Griffiths, R. R. (2003). Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence, 70, S55-72. doi:10.1016/S0376-8716(03)00099-1
3. Berman, M. L., Briggs, G. G., Bogh, P., Mannel, R., Manetta, A., & DiSaia, P. J. (1990). Simplified postoperative patient-controlled analgesia on a gynecologic oncology service. Gynecologic Oncology, 38, 55-58. doi:10.1016/0090-8258(90)90011-9
4. Carter, L. P., & Griffiths, R. R. (2009). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence, 105, S14-25. doi:10.1016/j.drugalcdep.2009.04.00
5. CDC. (2011). Drug Overdose Deaths Florida, 2003-2009. Center for Disease Control and Prevention MMWR, 60, 869-872.
6. Comer, S. D., Ashworth, J. B., Foltin, R. W., Johanson, C. E., Zacny, J. P., & Walsh, S. L. (2008). The role of human drug self-administration procedures in the development of medications. Drug and Alcohol Dependence, 96, 1-15. doi:10.1016/j.drugalcdep.2008.03.001
7. Comer, S. D., Collins, E. D., & Fischman, M. W. (1997). Choice between money and intranasal heroin in morphine-maintained humans. Behavioural Pharmacology, 8, 677-690. doi:10.1097/00008877-199712000-00002
8. Comer, S. D., Collins, E. D., Wilson, S. T., Donovan, M. R., Foltin, R. W., & Fischman, M. W. (1998). Effects of an alternative reinforcer on intravenous heroin self-administration by humans. European Journal of Pharmacology, 345, 13-26. doi:10.1016/S0014-2999(97)01572-0
9. Comer, S. D., Sullivan, M. A., Vosburg, S. K., Kowalczyk, W. J., & Houser, J. (2010). Abuse liability of oxycodone as a function of pain and drug use history. Drug and Alcohol Dependence, 109, 130-138. doi: 10.1016/j.drugalcdep.2009.12.01
10. Comer, S. D., Sullivan, M. A., Whittington, R. A., Vosburg, S. K., & Kowalczyk, W. J. (2008). Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology, 33, 1179-1191. doi:10.1038/sj.npp.1301479
11. Comer, S. D., Walker, E. A., & Collins, E. D. (2005). Buprenorphine/ naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology, 181, 664-675. doi: 10.1007/s00213-005-0023-6
12. Cone, E. J., Fant, R. V., Rohay, J. M., Caplan, Y. H., Ballina, M., Reder, R. F., Haddox, J. D. (2003). Oxycodone involvement in drug abuse deaths: A DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. Journal of Analytical Toxicology, 27, 57-67; discussion 67.
13. DEA. (2009). Drugs and chemicals of concern: Oxycodone. Office of Diversion Control, http://www.deadiversion.usdoj.gov/drugs_concern/ oxycodone/summary.htm
14. Donny, E. C., Brasser, S. M., Bigelow, G. E., Stitzer, M. L., & Walsh, S. L. (2005). Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction, 100, 1496-1509. doi:10.1111/j.1360-0443.2005.01232.x
15. Eisenberg, E., Midbari, A., Haddad, M., & Pud, D. (2010). Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects. Pain, 151, 104-109. doi:10.1016/ j.pain.2010.06.02
16. FDA. (2003). Abuse liability assessment and drug dependence: Scientific and regulatory considerations in drug development. http://www.fda.gov/downloads/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ UCM180870.pdf
17. Fraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961). Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test. The Journal of Pharmacology and Experimental Therapeutics, 133, 371-387.
18. Hart, C. L., Haney, M., Foltin, R. W., & Fischman, M. W. (2000). Alternative reinforcers differentially modify cocaine self-administration by humans. Behavioural Pharmacology, 11, 87-91. doi:10.1097/ 00008877-200002000-00010
19. Jones, B. E., & Prada, J. A. (1975). Drug-seeking behavior during methadone maintenance. Psychopharmacologia, 41, 7-10. doi:10.1007/ BF00421297
20. King, S. J., Reid, C., Forbes, K., & Hanks, G. (2011). A systematic review of oxycodone in the management of cancer pain. Palliative Medicine, 25, 454-470. doi:10.1177/0269216311401948
21. Lofwall, M. R., Nuzzo, P. A., & Walsh, S. L. (2011). Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers. Drug and Alcohol Dependence, Epub ahead of print. doi:10.1016/j.drugalcdep.2011.11.01
22. Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
23. Mello, N. K., Mendelson, J. H., Kuehnle, J. C., & Sellers, M. S. (1981). Operant analysis of human heroin self-administration and the effects of naltrexone. The Journal of Pharmacology and Experimental Therapeutics, 216, 45-54.
24. Mello, N. K., Mendelson, J. H., & Kuehnle, J. C. (1982). Buprenorphine effects on human heroin self-administration: An operant analysis. The Journal of Pharmacology and Experimental Therapeutics, 223, 30-39.
25. Mello, N. K., & Mendelson, J. H. (1980). Buprenorphine suppresses heroin use by heroin addicts. Science, 207, 657-659. doi:10.1126/science .7352279
26. Mercadante, S. (2010). Management of cancer pain. Internal and Emergency Medicine, 5, 31-35. doi:10.1007/s11739-010-0448-8
27. Meyer, R. E., Mirin, S. M., Altman, J. L., & McNamee, H. B. (1976). A behavioral paradigm for the evaluation of narcotic antagonists. Archives of General Psychiatry, 33, 371-377. doi:10.1001/archpsyc.1976 .01770030073011
28. Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011). The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction, 106, 1460-1473. doi:10.1111/j.1360-0443.2011.03424.x
29. Parker, R. K., Holtmann, B., & White, P. F. (1991). Patient-controlled analgesia. Does a concurrent opioid infusion improve pain management after surgery? Journal of the American Medical Association, 266, 1947- 1952. doi:10.1001/jama.1991.03470140059024
30. Pasternak, G. W. (2005). Molecular biology of opioid analgesia. Journal of Pain and Symptom Management, 29, S2-9. doi:10.1016/j.jpain symman. 2005.01.011
31. SAMHSA. (2011a). Drug Abuse Warning Network, 2009: National estimates of drug-related emergency department visits. HHS Publication No. (SMA) 11-4659, DAWN Series D-35. Rockville, MD: Substance Abuse and Mental Health Services Administration.
32. SAMHSA. (2011b). Results from the 2010 National Survey on Drug Use and Health: Summary of national findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration.
33. Stitzer, M. L., McCaul, M. E., Bigelow, G. E., & Liebson, I. A. (1983). Oral methadone self-administration: Effects of dose and alternative reinforcers. Clinical Pharmacology and Therapeutics, 34, 29-35. doi: 10.1038/clpt.1983.124
34. Stoops, W. W., Hatton, K. W., Lofwall, M. R., Nuzzo, P. A., & Walsh, S. L. (2010). Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: Abuse potential and relative potencies. Psychopharmacology, 212, 193-203. doi:10.1007/s00213-010-1942-4
35. Stoops, W. W., Lile, J. A., & Rush, C. R. (2010). Monetary alternative reinforcers more effectively decrease intranasal cocaine choice than food alternative reinforcers. Pharmacology, Biochemistry, and Behavior, 95, 187-191. doi:10.1016/j.pbb.2010.01.003
36. Walsh, S. L., Donny, E. C., Nuzzo, P. A., Umbricht, A., & Bigelow, G. E. (2010). Cocaine abuse versus cocaine dependence: Cocaine selfadministration and pharmacodynamic response in the human laboratory. Drug and Alcohol Dependence, 106, 28-37. doi:10.1016/j.drugalcdep .2009.07.011
37. Walsh, S. L., Heilig, M., Nuzzo, P. A., Henderson, P., & Lofwall, M. R. (2012). Effects of the NK(1) antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addiction Biology, ePub ahead of print. doi:10.1111/j.1369-1600.2011.00419.x
38. Walsh, S. L., Nuzzo, P. A., Lofwall, M. R., & Holtman, J. R., Jr. (2008). The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug and Alcohol Dependence, 98, 191-202. doi:10.1016/j.drugalcdep.2008.05. 007
39. Zacny, J. P., Divane, W. T., & de Wit, H. (1992). Assessment of magnitude and availability of a non-drug reinforcer on preference for a drug reinforcer. Human Psychopharmacology: Clinical and Experimental, 7, 281-286. doi:10.1002/hup.470070408
40. Zacny, J. P., & Gutierrez, S. (2009). Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug and Alcohol Dependence, 101, 107-114. doi:10.1016/j.drugalcdep.2008.11.013